A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model

• Published in: International journal of pharmaceutics Vol. 592; p. 120037
• Main Authors: Guo, Rui, Yang, Yun, Zhang, Di, Du, Jiang, Zhu, Xinxing, Liu, Yanli, Yang, Fen, Lin, Juntang
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.01.2021
• Subjects: Bispecific immunotoxin; HER2-target; PDGFRβ-target; PE toxin; Transcriptome sequencing; PE toxin; Transcriptome sequencing; HER2-target; PDGFRβ-target; Bispecific immunotoxin
• ISSN: 0378-5173; 1873-3476; 1873-3476
• DOI: 10.1016/j.ijpharm.2020.120037

[Display omitted] •Designed a bispecific immunotoxin with a long half-life targeting HER2 and PDGFRβ of tumor tissue.•Transcriptome sequencing was performed to detect the differentially expressed genes after antitumor in vivo.•The potential mechanism of antitumor of bispecific immunotoxin was preliminarily analyzed. Multiple signaling pathways are usually involved in the development of tumors. Compared with monospecific antibodies, bispecific antibodies can recognize two different antigens at the same time, so they are more suitable for treating tumor diseases with complex etiology. Immunotoxins have good antitumor activity, however, single targeting limits their effectiveness. Herein, we designed a Pseudomonas exotoxin A (PE)-based bispecific immunotoxin IgBD-HER2-PDGFRβ-PE38 which could distinguish HER2 and PDGFRβ target in tumor. Meanwhile, IgG-affinity could extend the serum retention of immunotoxins after in vivo injection. In this work, we first detected the selective binding of the immunotoxins and antitumor effect in vitro. Compared with control group, IgBD-HER2-PDGFRβ-PE38 exhibited improved efficacy against HER2-positive tumors in an NCI-N87 subcutaneous xenograft model. Then, transcriptome sequencing was performed on tumor tissue originating from different treatment groups of mice bearing NCI-N87 tumors. Seven significantly differentially expressed genes were screened based on human genes, and the differential mouse genes were enriched based on the Reactome Pathway Database. At last, the RNA sequencing results were verified by real-time PCR and ELISA. Therefore, the new construct bispecific immunotoxin represents a potentially attractive therapeutic modality, and the proposed strategy make them promising for use in the development of anti-HER2 cancer therapeutics.